Rich, Proprietary Data Fueled R&D

Anumana leverages the largest combined dataset of electrophysiological data, longitudinal patient history, and outcomes in the world. This dataset was developed from multi-year, exclusive data partnerships with leading academic medical centers from Anumana’s parent company, nference. This real-world evidence generation platform, nSights, is inclusive of 11M patients spanning 20+ years and transforms unstructured data (i.e. clinical notes, echocardiogram reports) and semi-structured (i.e. lab tests, medications, appointments, etc) data into labeled data format at scale. This extensive "deep data" platform fuels Anumana's research and development.

Cutting-Edge AI Medical Device Solutions

Anumana transforms research-grade algorithms into medical devices, conducting necessary clinical validation for regulatory clearance, and working with leading clinical experts around the world. Anumana's portfolio includes dozens of first-in-class algorithms, including ECG-AI algorithms for early disease detection and EGM-AI algorithms to improve EP procedures.

Anumana has a robust FDA-ready pipeline of ECG-AI algorithms, with 100+ peer-reviewed publications that showcase the potential of these algorithms for early cardiovascular disease detection and improved prognosis.

In addition to our detection algorithms, Anumana hopes to expand into perioperative cardiac care by developing novel generative AI imaging and visualization technologies. Anumana's potential perioperative technology will feature real-time imaging platforms and predictive algorithms for common interventions under structural heart, interventional cardiology, and electrophysiology procedures. 

Download Our One-Pager

Featuring key corporate highlights and an overview of Anumana's technology